World's largest eye bank launches research institute

Article

The world's largest eye bank, The Tampa Lions Eye Institute for Transplant and Research, Inc. in Florida, which has supplied over 30,000 corneas for transplant and 50,000 eyes for research worldwide over the past 30 years, is to open a state-of-the-art research facility.

The world's largest eye bank, The Tampa Lions Eye Institute for Transplant and Research, Inc. in Florida, which has supplied over 30,000 corneas for transplant and 50,000 eyes for research worldwide over the past 30 years, is to open a state-of-the-art research facility.

"The LEITR expansion means that, for the first time, diseased as well as healthy human eye tissue will be available to us for research," says Dr Henry Edelhauser, Ferst Professor at Emory University Eye Center. "This availability of a full spectrum of human eye tissue will improve our understanding of the underlying events that lead to blindness. Even more importantly, what we learn will eventually have a tremendous, positive impact on quality of life for patients with blinding diseases."

Key to the successful advancement of ocular tissue research is having the highest quality human tissue available. Over the years, LEITR recognized that time between tissue donor death and tissue recovery was essential. Current methods of providing tissue, particularly overnight shipping to facilities, has greatly affected the quality of that tissue. Now, researchers will have a repository of high-quality human ocular tissue on site at LEITR.

LEITR is also forming a distinguished advisory board, consisting of opinion leaders from top academic eye institutions around the country. Collaborative relationships with academic, government, and pharmaceutical industry research centres will be established to facilitate accelerated drug innovation, timely clinical trials and a foundation for best research practices.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.